These findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
Abstract
The infiltration of CD8+ T cells into the hepatocellular carcinoma (HCC) microenvironment is a well-established determinant of immunotherapy efficacy and patient prognosis. However, the regulatory mechanisms governing this process and the therapeutic strategies capable of modulating it remain largely unexplored. Here, we identify HCC-IN-247 as a candidate compound that enhances IFNβ-driven CD8+ T cell infiltration both in vitro and in vivo. Mechanistic investigations reveal that the long noncoding RNA LINC02084 directly interacts with the transcription factor GLIS1 and facilitates its recruitment to the IFNβ promoter. HCC-IN-247 was identified through screening to target the LINC02084-GLIS1 binding interface, thereby stabilizing this RNA–protein complex. Stabilization of the complex significantly enhances IFNβ transcription, which in turn upregulates CXCL10 and CXCL11 expression and promotes CD8+ T cell infiltration. Furthermore, this study engineered a nanoparticle-based delivery system, designated Lip@RA@BSA-PD-L1/IN-247, for the codelivery of HCC-IN-247 and the anti-PD-L1 antibody atezolizumab in HCC treatment. These nanoparticles exhibited robust tumor-specific accumulation and elicited potent synergistic antitumor activity against HCC in mice. Collectively, our findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
A critical role is revealed for MMGT1 in shaping the TNBC immune microenvironment and targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes, suggesting that targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes.
Findings reveal that cancer cell-derived anaphylatoxin C5a plays a pivotal role in promoting an inhibitory TIME in liver tumor tissues and blocking the C5a/C5ar1 axis in combination with immune checkpoint inhibitors could represent a promising strategy for treating HCC.
Run Huang, Tian-Hao Chu, Guiqi Zhu et al.· Cancer Letters· 0 citations
It is showcased that CD70-directed CAR-T cell therapy remodels the post-treatment immune landscape towards resolution of inflammation and reduced immunosuppression, supporting sustained immune surveillance.
A. Kourtesakis, D. Agardy, Clara Tejido Dierssen et al.· Oncoimmunology· 0 citations
Summary Emerging evidence associates CXCR5 expression with immunotherapy outcomes; however, the intrinsic role of tumor-derived CXCR5 in modulating chemo-immunotherapy sensitivity in triple-negative breast cancer (TNBC) remains uncharacterized. This study was conducted using murine 4T1 and human MDA-MB-231 TNBC models....
W. Feng, Jin Yan, Xue Gong et al.· iScience· 0 citations
We investigated the role of tumor microenvironment (TME) in evolution of liver cirrhosis to hepatocellular carcinoma (HCC). Nonmalignant hepatic tissues, including chronic hepatitis and cirrhosis, retained expression of liver specific miR-122 and hepatocyte nuclear factor 4 (HNF-4) transcription factor and exhibited an...
Gerard J. Nuovo, T. Heineman, E. Tili et al.· Proceedings of the National...· 0 citations
SIRPA functions as a previously unrecognized intrinsic regulator of T cell apoptosis in HCC and may enhance anti-tumor immunity by preventing T cell apoptosis, representing a promising immunotherapeutic strategy.
Xue Zhang, Li-Ying Ren, Pu Chen et al.· Journal for ImmunoTherapy of...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.